The U.S. Food and Drug Administration (FDA) has announced a significant shift in its policy, stating it will begin conducting unannounced, surprise inspections of foreign pharmaceutical manufacturing facilities. This move is a direct follow-up to a new executive order and policy announcements from the Trump administration aimed at promoting domestic drug production and ensuring regulatory consistency.

According to a report released on September 12 by the Korea Biotechnology Industry Organization's Bio-economy Research Center, the FDA plans to drastically increase its unannounced inspections of overseas drug manufacturing facilities. The initiative stems from an executive order issued by U.S. President Trump on May 5, which directed the FDA to increase overseas inspection fees, improve risk-based inspection systems, and publicly disclose the number of inspections conducted per country.

At the Bio Innovation Conference in Maryland on September 4, Marty Makary, the FDA Director, stated that the previous practice of giving advance notice for inspections of foreign facilities was "nothing short of a joke." He emphasized that from now on, foreign facilities would be subject to the same no-notice inspections as their U.S. counterparts. "Foreign companies have had a much lighter inspection burden than U.S. companies," he noted, adding that advance notice allowed for document fabrication and concealment of violations, which undermined the credibility of the inspections.

In response to the policy change, global clinical research organization (CRO) Parexel warned in a recent blog post that there would be a significant increase in "unannounced inspections" for overseas manufacturers. Parexel recommended several concrete countermeasures for companies, including:

Conducting regular mock inspections.
Establishing clear response plans.
Keeping documentation up-to-date.
Strengthening training protocols.
Implementing robust change management.

The Korea Biotechnology Industry Organization advised that Korean companies must proactively prepare for these changes. The association warned that unprepared overseas manufacturers who are found to be non-compliant during a surprise inspection could face production disruptions and supply chain instability.